Showing 301 results
  • PDF
    lock
    Products / Fact Sheet
    Kymriah® (tisagenlecleucel) in children and young adults with B-cell ALL that is refractory or relapsed at least twice

    Kymriah® (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US

  • PDF
    lock
    Products / Fact Sheet
    The JULIET Clinical Trial

    The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.

  • PDF
    lock
    Products / Fact Sheet
    How does ACZ885 work?

    ACZ885 is a human monoclonal antibody, which is a protein that is designed to bind to only one substance in the body. ACZ885 is designed to bind to human interleukin-1β (IL-1β).

  • PDF
    lock
    Products / Fact Sheet
    Erenumab (AMG 334) Key Clinical Trials By The Numbers

    Erenumab has been studied in several large, global, randomized, double-blind, placebo-controlled studies to assess its safety and efficancy in migraine prevention.

  • PDF
    lock
    Products / Fact Sheet
    About erenumab AMG 334

    Erenumab is designed to specifically block the CGRP receptor, which plays a critical role in migraine activation. It is being co-developed by Novartis and Amgen.

  • What do you know about noncommunicable diseases?
    Video
    lock
    Corporate Responsibility / Video
    What do you know about noncommunicable diseases?

    The menace of noncommunicable diseases (NCDs) like cardiovascular disease, diabetes and cancer in the developing world is increasing. New solutions like Novartis Access are needed to ensure more people are trained to prevent, diagnose and treat these diseases, and patients have access to affordable quality medicines.

  • The Museum of MS
    Video
    lock
    Disease education / Video
    The Museum of MS

    Welcome to the first-ever Museum of MS, a place that celebrates how people living with multiple sclerosis (MS) overcome the challenges or adapt to the symptoms of MS in their daily lives.

  • Novartis and the International Red Cross partner to provide medicines to Syrian refugees
    Video
    lock
    Corporate Responsibility / Video
    Novartis and the International Red Cross partner to provide medicines to Syrian refugees

    Novartis Access is partnering with the International Committee of the Red Cross to provide access to medicines for Syrian refugees and their host communities in Lebanon.

  • Novartis Access: How We'll Expand Access to Healthcare
    Video
    lock
    Corporate Responsibility / Video
    Novartis Access: How We'll Expand Access to Healthcare

    Novartis brought together European stakeholder including NGOs, academia, governments as well as Novartis associates to present and debate Novartis Access, a new program intended to increase access to medicine for patience at ever level of income. Novartis associates share their reactions.

  • Experts gather to explore response to chronic illness in poor countries
    Video
    lock
    Corporate Responsibility / Video
    Experts gather to explore response to chronic illness in poor countries

    On November 29, global health experts from the Novartis Foundation, Novartis Access, NGOs and academia gathered at our Basel headquarters to discuss the chronic disease challenge in developing countries.

  • ALK+ Non-Small Cell Lung Cancer Patient Video: Miriam & Joel
    Video
    lock
    Disease Awareness / Video
    ALK+ Non-Small Cell Lung Cancer Patient Video: Miriam & Joel

    Miriam, a patient with Anaplastic Lymphoma Kinase (ALK+) non-small cell lung cancer (NSCLC), and her husband Joel describe their experience with the disease.

  • ALK+ Non-Small Cell Lung Cancer Patient Video: Anne Marie
    Video
    lock
    Disease Awareness / Video
    ALK+ Non-Small Cell Lung Cancer Patient Video: Anne Marie

    Anne Marie, a patient with Anaplastic Lymphoma Kinase (ALK+) non-small cell lung cancer (NSCLC), describes her experience with the disease.